«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 10

Page:

1886-1889

Research Field:

Publishing date:

Info

Title:

Correlation between the ratio of schistocytes in peripheral blood and the clinical characteristics of patients with transplantation-associated thrombotic microangiopathy

Author(s):

JIAO Yang¹; JIANG Yanhong¹; WANG Hao¹; BI Lijun²; XU Qingxia¹

1.Department of Clinical Laboratory,the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Zhengzhou Key Laboratory of Digestive Tumor Markers,Henan Zhengzhou 450008,China;2.Institute of Biophysics,Chinese Academy of Sciences,Guangdong Foshan 528000,China.

Keywords:

schistocytes; transplantation; thrombotic microangiopathy; correlation

PACS:

R733

DOI:

10.3969/j.issn.1672-4992.2023.10.021

Abstract:

Objective:To analyze the correlation between the ratio of schistocytes in peripheral blood and the clinical characteristics of patients with transplantation-associated thrombotic microangiopathy (TA-TMA).Methods:Laboratory and clinical data of patients with TA-TMA after receiving hematopoietic stem cell transplantation (HSCT) in hematology department of the Affiliated Cancer Hospital of Zhengzhou University from January 2014 to December 2021 were retrospectively reviewed.SPSS 21.0 software was used for statistical analysis.Results:There was a positive correlation between the ratio of peripheral blood schistocytes in TA-TMA patients and transplant-TMA time (r=0.532,P=0.006),however,there was a negative correlation between the ratio of peripheral blood schistocytes in TA-TMA patients and the therapeutic effect of TA-TMA (r=-0.709,P=0.000).The optimal cut-off value of the ratio of peripheral blood schistocytes in patients with TA-TMA to predict the clinical treatment effect was 3.1% (sensitivity 76.9%,specificity 83.3%).Conclusion:The ratio of schistocytes in peripheral blood is a relatively intuitive laboratory indicator for the diagnosis of TA-TMA.It increases with the increase of transplantation-TMA time,but the curative effect will be worse.3.1% can be used as a critical value for predicting curative effect.Below this value,the treatment effect is better.

References:

[1]ARDISSINO G,CAPONE V,TEDESCHI S,et al.Complement system as a new target for hematopoietic stem cell transplantation-related thrombotic microangiopathy£ÛJ£Ý.Pharmaceuticals (Basel),2022,15(7):845.
[2]BALDUINI CL.Images from the haematologica atlas of hematologic cytology:schistocytes in thrombotic microangiopathies£ÛJ£Ý.Haematologica,2022,107(9):2008.
[3]LESESVE JF,ALLA F,DUGU¦I F,et al.Evaluation of schistocyte monitoring after haematopoietic stem cell transplantation£ÛJ£Ý.Int J Lab Hematol,2011,33(4):343-356.
[4]RUUTU T,BAROSI G,BENJAMIN RJ,et al.Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy:results of a consensus process by an International Working Group£ÛJ£Ý.Haematologica,2007,92(1):95-100.
[5]Éòã©,ÕÔÓÀÇ¿,ÖܵÀ±ó,µÈ.ѪҺ²¡Õï¶Ï¼°ÁÆЧ±ê×¼£ÛM£Ý.±±¾©:¿Æѧ³ö°æÉç,2018:97-109. SHEN T,ZHAO YQ,ZHOU DB,et al.Hematological diagnosis and therapeutic criteria£ÛM£Ý.Beijing:People's Health Publishing House,2018:97-109.
[6]KENNEDY GA,KEAREY N,BLEAKLEY S,et al.Transplantation-associated thrombotic microangiopathy:effect of concomitant GVHD on efficacy of therapeutic plasma exchange£ÛJ£Ý.Bone Marrow Transplant,2010,45(4):699-704.
[7]LASKIN BL,GOEBEL J,DAVIES SM,et al.Small vessels,big trouble in the kidneys and beyond:hematopoietic stem cell transplantation-associated thrombotic microangiopathy£ÛJ£Ý.Blood,2011,118(6):1452-1462.
[8]ZINI G,D' ONOFRIO G,BRIGGS C,et al.ICSH recommendations for identification,diagnostic value,and quantitation of schistocytes£ÛJ£Ý.Int J Lab Hematol,2012,34(2):107-116.
[9]KANAMORI H,TAKAISHI Y,TAKABAYASHI M,et al.Clinical significance of fragmented red cells after allogeneic bone marrow transplantation£ÛJ£Ý.Int J Hematol,2003,77(2):180-184.
[10]PALMA LMP,VAISBICH-GUIMAR¦GES MH,SRIDHARAN M,et al.Thrombotic microangiopathy in children£ÛJ£Ý.Pediatr Nephrol,2022,37(9):1967-1980.
[11]SABULSKI A,JODELE S.What complements complement in transplant-associated thrombotic microangiopathy£ÛJ£Ý? Br J Haematol,2022,199(4):477-479.
[12]KHOSLA J,YEH AC,SPITZER TR,et al.Hematopoietic stem cell transplant-associated thrombotic microangiopathy:current paradigm and novel therapies£ÛJ£Ý.Bone Marrow Transplant,2018,53(2):129-137.
[13]ÍõÕ×îá.Ѫ˨ÐÔ΢Ѫ¹Ü²¡¼ø±ðÕï¶ÏÓëÖÎÁƵĽøÕ¹£ÛJ£Ý.ÖлªÑªÒºÑ§ÔÓÖ¾,2015,36(3):254-257. WANG ZY.Advances in differential diagnosis and treatment of thrombotic microangiopathy£ÛJ£Ý.Chinese Journal of Hematology,2015,36(3):254-257.
[14]JODELE S,LICHT C,GOEBEL J,et al.Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy£ÛJ£Ý.Blood,2013,122(12):2003-2007.
[15]Àî·ãÁÖ,ÈÎÓê,ÍõƼ.ÔìѪ¸Éϸ°ûÒÆÖ²ºó²¢·¢ÉöÏà¹ØÐÔѪ˨ÐÔ΢Ѫ¹Ü²¡µÄÑо¿½øÕ¹£ÛJ£Ý.ÖлªÆ÷¹ÙÒÆÖ²ÔÓÖ¾,2017,38(1):58-61. LI FL,REN Y,WANG P.Research progress of renal associated thrombotic microangiopathy after hematopoietic stem cell transplantation£ÛJ£Ý.Chinese Journal of Organ Transplantation,2017,38(1):58-61.
[16]BALASSA K,ANDRIKOVICS H,REMENYI P,et al.The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy£ÛJ£Ý.Bone Marrow Transplant,2015,50(10):1321-1325.
[17]KRAFT S,BOLLINGER N,BODENMANN B,et al.High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease£ÛJ£Ý.Bone Marrow Transplant,2019,54(4):540-548.
[18]YE Y,ZHENG W,WANG J,et al.Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation:a nested case control study£ÛJ£Ý.Hematol Oncol,2017,35(4):821-827.
[19]ZHANG XH,LIU X,WANG QM,et al.Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation:Risk factors and outcome£ÛJ£Ý.Eur J Haematol,2018,100(2):171-181.
[20]GARC¦PA-MART¦PN P,ALARC¦„N-PAYER C,L¦„PEZ-FERN¦BNDEZ E,et al.Transplantation-associated thrombotic microangiopathy in patients treated with sirolimus and cyclosporine as salvage therapy for graft-versus-host disease£ÛJ£Ý.Ann Pharmacother,2015,49(9):986-994.

Memo

Memo:

National Natural Science Foundation of China(No.82203572£©£»¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¨±àºÅ£º82203572£©

Common functions

Last Update: 1900-01-01